PORTLAND, Ore., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported better-than-expected preliminary results in the Company’s chronic kidney disease study being conducted on the island of Bonaire. Statistical analysis of the preliminary study results indicates, at a 95 percent confidence level, that three out of four consumers could reasonably expect a ten per cent increase in filtration rate. Dr. Hausman stated, “Our preliminary results exceeded our expectations and represent new hope for patients facing the challenge of stage 2,3, or 4 CKD.” The data, analyzed by an independent statistical analysis organization, reflect results for 22 study participants, all of whom suffer from stage 2, 3 or 4 CKD. Entia is also conducting an additional study that is underway in the South American nation of Colombia.
According to the National Kidney Foundation, chronic kidney disease effects 26 million people in the U.S. The incidence of recognized CKD in people aged 65 and older has more than doubled between 2000 and 2008(1). The annual cost to treat CKD Medicare patients is $57.5 Billion, and represents 28% of the Medicare budget(2). Tragically, the disease represents over 85 thousand deaths in the U.S. each year and is the ninth leading cause of death.
Entia Biosciences says that it anticipates that adding its medical food supplement to existing standards of medical care for CKD will cost consumers only $2.00 per day.
Hector Rodriguez, MD, PhD, a respected nephrologist who has served as a consultant to Entia, commented on these early results saying, “I have advised Entia Biosciences for several years during the development of the ErgoD2 medical food product. Early results from the recent Entia clinical study in stage 2, 3 and 4 CKD patients appears to confirm that promise. The potential for a significant improvement in the standard of care for chronic kidney disease is possible.” Dr. Rodriguez is the Medical Director of a free-standing dialysis center located near the Cedars-Sinai Medical Center campus in Los Angeles.
Michael Hermelijn, MD and Medical Director of the Bonaire Medical Clinic, Bonaire, BES, where the initial clinical results were obtained, has advised Entia that, “Preliminary results for the ErgoD2 clinical study…are very interesting and encouraging. Patients report improvement in their quality of life. This improvement is borne out by impressive results in critical physiological measurements of kidney function. If these results continue in helping patients, and I believe they will, this could be an important development in helping patients with this life-threatening disease.”
The Company will formally introduce the product to healthcare practitioners at the American Society of Nephrology, Kidney Week Convention in November, 2016. At that meeting, results for additional patients participating in the study will be available. In addition, Entia will be an exhibitor at the conference.
Entia Biosciences plans on introducing its initial medical food product offering to consumers by April 1, 2017.
Requests for additional information should be directed to firstname.lastname@example.org or by calling (844) 559-9910.
About Entia Biosciences, Inc.
Entia (OTCQB:ERGO) discovers, scientifically validates, develops and markets patented, pharmaceutical-grade organic compounds that include its revolutionary ErgoD2®. The Company is a leading authority on the clinical effects of oxidative stress, iron-related disorders and free radical reactions in mammals; it is bringing this expertise to the nutraceutical and medical foods markets. Entia also develops and markets health-related cosmeceuticals.
Entia Biosciences, Inc. is headquartered in Sherwood, Oregon, a Portland suburb.
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences, Inc. with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2015 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contact: Carl Johnson or Tim Timmins (844-559-9910)
Source:Entia Biosciences, Inc.